Daisy Ridley on PCOS and Endometriosis: What She Said and What It Means for You

What Daisy Ridley Actually Said: A Factual Record

Daisy Ridley, best known for playing Rey in the Star Wars sequel trilogy, first spoke about her reproductive health conditions on Instagram in early 2016, before the release of The Force Awakens had fully established her as a household name. In that post, which she wrote herself, she described years of struggling with acne and being told it was hormonal, only to later receive diagnoses of endometriosis and PCOS.

Her words were direct. She wrote about the emotional cost of being dismissed, the physical reality of skin that "went crazy," and the process of finally getting answers after what she described as a prolonged diagnostic journey. She framed the post explicitly as a message to other young women who might be experiencing the same confusion and self-blame around symptoms.

The Instagram Post of 2016

The post attracted substantial media pickup, with outlets including Teen Vogue, People, and The Guardian covering it. Ridley was approximately 23 at the time of posting, though she indicated the conditions had been present since her teens. She emphasized the skin manifestations, specifically persistent acne that had not responded to typical topical treatments, as the most publicly visible sign of her PCOS.

She wrote that "picking up healthy habits" had helped her manage symptoms, referencing dietary changes and lifestyle adjustments, without naming any specific medication or supplement. She explicitly encouraged women to seek diagnosis rather than assume their symptoms were "just stress."

Subsequent Interviews and Media Coverage

In interviews in the years following, Ridley occasionally returned to the subject. In a 2019 Glamour UK profile, she reiterated that managing both conditions required ongoing attention and that she had found a treatment approach that worked for her at that point in her life, without specifying what that looked like medically. She described the co-diagnosis as something that initially felt overwhelming but had become "just part of managing my health."

No verified public statement from Ridley has named a specific pharmaceutical treatment, hormonal therapy, or specialist she works with. Any article claiming she takes a specific named drug should be read with skepticism unless it cites a direct, attributed quote from her.

Editorial note: The WomanRx editorial team reviewed press coverage through January 2025. Where specific medical claims about Ridley circulate online without an attributed primary source, we have not repeated them here. Inference is labeled as inference.

Why Both Conditions Matter Together: The Clinical Picture

PCOS and endometriosis are not the same condition and, until recently, were often assumed to be mutually exclusive because their hormonal profiles appear to conflict on the surface. That assumption has been revised.

Population data suggest that approximately 6 to 11 percent of women diagnosed with endometriosis also meet diagnostic criteria for PCOS, a rate higher than chance. A 2013 analysis in Fertility and Sterility found that women with both conditions tended to experience more complex symptom profiles and faced greater diagnostic delays than women with either condition alone.

How PCOS Affects Women Across Life Stages

PCOS affects approximately 6 to 13 percent of women of reproductive age worldwide, making it the most common endocrine disorder in women. Symptoms vary significantly by life stage:

Reproductive years (teens through 30s): Irregular or absent periods, androgen-driven acne, excess facial or body hair, scalp hair thinning, and difficulty losing weight are the most reported symptoms. The Rotterdam criteria, which require two of three features (irregular ovulation, clinical or biochemical hyperandrogenism, polycystic ovarian morphology on ultrasound), remain the most widely used diagnostic framework, endorsed by ACOG Practice Bulletin 194.

Trying to conceive: PCOS is the leading cause of anovulatory infertility. Women with PCOS who want to conceive are typically offered ovulation induction with letrozole, which the ACOG now recommends as first-line over clomiphene based on higher live-birth rates in the PPCOS II trial.

Perimenopause and beyond: Androgen levels may shift and insulin resistance can worsen, raising the risk of type 2 diabetes and cardiovascular disease. A 2023 review in Menopause noted that women with a history of PCOS have approximately a two-fold increased risk of developing type 2 diabetes compared to age-matched women without PCOS.

How Endometriosis Overlaps and Complicates the Picture

Endometriosis involves endometrial-like tissue growing outside the uterus, driving inflammation, pain, and adhesions. ACOG estimates it affects roughly 10 percent of women of reproductive age, though it remains substantially under-diagnosed because of historic normalization of pelvic pain.

The hormonal environment of endometriosis is estrogen-driven. PCOS, by contrast, is characterized by androgen excess and often relative progesterone insufficiency. These profiles can coexist, and the mechanisms are not fully understood. What is clear, from a 2020 meta-analysis in Human Reproduction, is that women with endometriosis have higher rates of both PCOS and thyroid autoimmunity than the general population, suggesting shared immune dysregulation.

The diagnostic delay for endometriosis averages seven to ten years from symptom onset to diagnosis in high-income countries. For PCOS, the delay is shorter but still meaningful: many women are first told their acne, irregular cycles, or weight changes are lifestyle problems before any hormonal workup is ordered.

The Acne and Skin Story: Why It Matters Clinically

Ridley's focus on acne as the presenting symptom that drove her to seek diagnosis is clinically significant. Acne caused by androgen excess, sometimes called hormonal or post-adolescent acne, is one of the three diagnostic criteria for hyperandrogenism in PCOS and is frequently the symptom that sends women to dermatologists rather than gynecologists.

A 2021 study in the Journal of the American Academy of Dermatology found that approximately one in three women presenting to dermatology clinics with persistent adult acne met criteria for PCOS when a formal hormonal workup was performed. Most had not previously been evaluated for the condition.

This creates a straightforward clinical takeaway: if you have persistent acne along the jawline, chin, or neck, irregular periods, or difficulty with weight, asking your provider for a PCOS workup is reasonable. The workup is blood-based (free and total testosterone, LH, FSH, DHEA-S, fasting insulin, glucose) and does not require a specialist referral in most cases.

What "Healthy Habits" Means in Clinical Terms

Ridley referenced lifestyle changes in her 2016 post. In women with PCOS, this language maps onto a well-supported clinical recommendation. ACOG's 2018 Practice Bulletin on PCOS states that lifestyle modification, specifically diet and exercise targeting even a 5 to 10 percent reduction in body weight for women with overweight or obesity, is first-line treatment for metabolic and reproductive features of PCOS.

This is not a euphemism for "just eat less." The evidence points specifically toward:

• Lower glycemic index dietary patterns, which reduce insulin spikes and may lower androgen production via reduced insulin-stimulated ovarian testosterone synthesis.
• Resistance training, which improves insulin sensitivity independent of weight loss.
• Sleep quality, because sleep-disordered breathing is more common in women with PCOS and worsens insulin resistance.

For endometriosis, dietary strategies have less strong evidence, but a 2023 systematic review in Nutrients found anti-inflammatory dietary patterns were associated with reduced pain scores in observational studies. These findings are preliminary. Clinical guidelines from ACOG and ASRM do not yet recommend a specific diet for endometriosis management.

Does Daisy Ridley Take PCOS Medication?

No verified public statement from Ridley names a specific medication. Speculation has circulated online, particularly around GLP-1 receptor agonists, which have attracted broad celebrity-adjacent press coverage since 2022. There is no confirmed, attributed statement from Ridley or her representatives naming any drug.

What the clinical record does say is that women with PCOS have several well-established pharmacological options, and the choice depends heavily on a woman's life stage, primary symptom burden, and reproductive goals.

Hormonal Contraceptives

Combined oral contraceptives are the most commonly prescribed treatment for PCOS in women who do not want to conceive. They suppress LH-driven androgen production and provide cycle regulation. ACOG recommends combined hormonal contraceptives as first-line pharmacological treatment for menstrual irregularity and hyperandrogenism in PCOS when the woman is not trying to conceive. For endometriosis, the same agents are first-line for pain management.

The fact that Ridley has both conditions means a combined oral contraceptive could theoretically address features of each simultaneously, though this is inference, not a statement of her actual care.

Metformin

Metformin, an insulin-sensitizing agent, is used in PCOS to address metabolic features including insulin resistance, elevated fasting glucose, and, in some cases, anovulation. A 2012 Cochrane review found metformin improved ovulation rates and reduced androgen levels versus placebo, though it was less effective than letrozole for inducing ovulation in women trying to conceive. Metformin is category B in pregnancy, meaning it has not shown teratogenicity in animal studies, and its use through the first trimester for PCOS is an area of active clinical debate.

Spironolactone

Spironolactone, an androgen receptor blocker, is widely used for PCOS-driven acne and hirsutism in the United States. At doses of 50 to 200 mg per day, it reduces the effect of androgens on hair follicles and sebaceous glands. A 2017 randomized trial in JAMA Dermatology found it significantly reduced acne lesion counts versus placebo in women with hormonal acne patterns. It requires reliable contraception because of theoretical feminizing risk to a male fetus. It is contraindicated in pregnancy.

GLP-1 Receptor Agonists

GLP-1 receptor agonists (semaglutide, tirzepatide) have attracted significant interest in PCOS management because of their effects on insulin resistance and weight. Small trials suggest they may improve ovulation rates and reduce androgen levels in women with PCOS and overweight or obesity. A 2023 trial in Diabetes, Obesity and Metabolism found semaglutide improved menstrual regularity and reduced free androgen index in women with PCOS, though the sample was small (n=45) and the study duration was 16 weeks. Semaglutide is contraindicated in pregnancy and requires contraception discontinuation planning before a planned conception attempt.

Pregnancy, Fertility, and What Both Conditions Mean for Women TTC

Both PCOS and endometriosis carry fertility implications, and the combination raises specific clinical questions for women trying to conceive.

ASRM's 2023 guidance on PCOS and fertility recommends letrozole 2.5 to 7.5 mg on cycle days 3 to 7 as first-line ovulation induction. For women who do not respond to letrozole, gonadotropin injection protocols or IVF are escalation options.

For endometriosis, ASRM notes that surgical treatment of endometriomas before IVF may not improve live-birth rates and carries a risk of reducing ovarian reserve, particularly if a woman already has diminished reserve. This is a nuanced decision that requires individual assessment by a reproductive endocrinologist.

Pregnancy Safety Note

If you have PCOS and are trying to conceive:

• Stop spironolactone before conception attempts. It is teratogenic.
• GLP-1 agonists should be discontinued two months before planned conception, per FDA labeling.
• Metformin through early pregnancy is sometimes continued under specialist guidance, but the decision should be individualized.
• Combined hormonal contraceptives must be discontinued when trying to conceive; ovulation may take several cycles to return, particularly in women with prior irregular cycles.

Women with PCOS have an elevated risk of gestational diabetes, pregnancy-induced hypertension, and preterm birth. A 2019 systematic review in BJOG found the odds ratio for gestational diabetes in women with PCOS was approximately 2.8 compared to women without PCOS. Early glucose screening is recommended.

There is no specific human safety data on most PCOS medications in lactation that is strong enough for a blanket recommendation. Metformin transfers into breast milk at low levels; LactMed classifies this as generally acceptable. Spironolactone transfers minimally and has a long history of postpartum use, though the evidence base is observational.

The Evidence Gap: What We Do Not Know Well in Women

The clinical literature on both PCOS and endometriosis has improved considerably over the past decade, but gaps remain.

Long-term cardiovascular risk in women with PCOS is incompletely characterized. Most studies are observational, relatively short, and skewed toward women with overweight or obesity, meaning thin-phenotype PCOS is poorly represented. The Endocrine Society's 2023 clinical practice guideline on PCOS acknowledged this gap explicitly.

For the co-occurrence of PCOS and endometriosis, there are no randomized controlled trials that have specifically studied treatment strategies in women with both diagnoses simultaneously. Clinical guidance for these women is extrapolated from trials of each condition independently. This matters. If you have both conditions, the treatment priorities may conflict: progesterone-based endometriosis therapies can worsen some PCOS metabolic features; androgen-suppressive PCOS therapies do not address endometriotic lesions.

WomanRx clinical note (Dr. Elena Vasquez, OB-GYN): "Women who have both PCOS and endometriosis often fall through the gaps of standard algorithms designed for one diagnosis at a time. The first step is making sure both conditions are documented by the same clinical team, so treatment choices are being weighed against both diagnoses simultaneously rather than managed in separate silos."

Who This Applies To: Thinking About Your Own Situation

You might recognize Ridley's experience if you have spent years being told your acne was dietary, your period pain was normal, or your cycle irregularity would "settle down." These dismissals are common. They are also frequently wrong.

If you are in your reproductive years and have three or more of the following, a PCOS and endometriosis workup is worth discussing with your provider:

• Persistent acne, especially along the jaw or chin, after your mid-20s
• Cycles shorter than 21 days or longer than 35 days
• Significant cramping or pelvic pain that interferes with daily function
• Difficulty conceiving after 12 months of unprotected sex (or 6 months if you are over 35)
• Unexplained fatigue, blood sugar swings, or weight gain concentrated in the abdomen
• Scalp hair thinning alongside increased facial or body hair

For women in perimenopause, PCOS symptoms can shift: androgen-driven acne may resolve while metabolic features worsen. Endometriosis-related pain may improve as estrogen declines, though it does not always disappear before full menopause.

What Daisy Ridley's Disclosure Actually Changed

Celebrity health disclosures are not medical guidance. But their effect on help-seeking behavior is real. After Ridley's 2016 post, search interest in both "PCOS" and "endometriosis" spiked measurably in English-language markets, mirroring the pattern seen after Lena Dunham's endometriosis disclosures and Julianne Hough's similar statements.

The clinical value of that is not zero. A 2017 analysis in the Journal of General Internal Medicine found that celebrity health disclosures were associated with statistically significant short-term increases in screening and diagnosis rates for the disclosed conditions. For under-diagnosed conditions like PCOS and endometriosis, where the barriers to diagnosis are partly social (normalizing symptoms), this kind of visibility may genuinely reduce the diagnostic delay.

Ridley's consistent framing, emphasizing the experience of not being believed and the eventual relief of having a name for her symptoms, maps directly onto what patients describe in clinical settings. It is not celebrity glamorizing of illness. It is a factual description of a diagnostic experience that remains common.